• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002755.SZ
Share

Beijing Aosaikang Pharmaceutical Co., Ltd. Stocks

CN¥ 14.57Last Updated 14.07.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 2.02B

CN¥ 14.57
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Operating within China, Beijing Aosaikang Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of pharmaceuticals, fine chemicals, and health products. Its diverse offerings include proton pump inhibitor injections, oncology medications, and active pharmaceutical ingredients (APIs), which are applied across key therapeutic areas like digestive disorders, cancer treatment, and infectious diseases. The company was founded in 2003 and is headquartered in Nanjing, China.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7

The average target price of 002755.SZ is 26.3 and suggests 78.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 23:31

Software developers' stocks plummeted following IBM's warning. What's wrong with the sector?

14.07.2026 23:07

Goldman Sachs set a new record for equity trading revenue. Its stock price soared

14.07.2026 22:06

Apple shares received a rare "sell" recommendation. An analyst identified risks to demand

14.07.2026 21:33

SpaceX will become the internet provider for Frontier flights. Why this matters

14.07.2026 20:52

BofA downgrades rating, TP on Papa John's amid turnaround doubts, tougher competition

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026